In each tumor type, variants with moderate-to-high impact in oncogenes were identified as follows: PDGFR-β c.2218C > T in urothelial carcinoma, ALK c.2662T > A, PDGFB c.748G > A, CTNNB1 c.94G > A, ABL1 c.1884T > G in adenocarcinoma, and NOTCH1 c.1445-2A > C, NOTCH1 c.1445-1G > C, NOTCH1 c.1445G > C, GLI2 c.529G > A in rhabdomyosarcoma (Table 7). This evidence concerns the gene ALK and adenocarcinoma.